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ABSTRACT Chronic respiratory symptoms, such as cough, wheeze and dyspnoea, are common in
children; however, most research has, with the exception of a few large-scale clinical cohort studies, been
performed in the general population or in small, highly-selected samples.
The Swiss Paediatric Airway Cohort (SPAC) is a national, prospective clinical cohort of children and
adolescents who visit physicians for recurrent conditions, such as wheeze and cough, and exercise-related
respiratory problems. The SPAC is an observational study and baseline assessment includes standardised
questionnaires for families and data extracted from hospital records, including results of clinically
indicated investigations, diagnoses and treatments. Outcomes are assessed through annual questionnaires,
monthly symptom reporting via mobile phone and follow-up visits.
The SPAC will address important questions about clinical phenotypes, diagnosis, treatment, and the
short- and long-term prognosis of common respiratory problems in children. The cohort currently
consists of 347 patients from four major hospitals (Bern, Zurich, Basel and Lucerne), with 70–80
additional patients joining each month. More centres will join and the target sample size is a minimum of
3000 patients.
The SPAC will provide real-life data on children visiting the Swiss healthcare system for common
respiratory problems and will provide a research platform for health services research and nested clinical
and translational studies.
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Introduction
Many children suffer during their childhood from repeated episodes of wheeze, cough, or dyspnoea [1–4].
These symptoms are typical for childhood asthma, but are also seen in other diseases. Childhood asthma
is characterised by a range of phenotypes that might reflect distinct aetiologies [5–9]. Symptoms vary over
time, with short-term diurnal and seasonal fluctuations and a variable long-term course. Factors determining
clinical course are poorly understood and the available prediction tools have limited accuracy [10]. In
addition, the diagnosis of asthma is not straightforward and making the distinction from healthy children
and children with other underlying problems can be difficult [11, 12].
Another common and possibly related respiratory problem in childhood is recurrent or chronic cough
(without wheeze), which affects up to 20% of preschool and schoolchildren [3, 13–15]. Chronic cough
is a key symptom of asthma and upper respiratory tract allergies, but also occurs as prolonged
post-infectious cough after viral or atypical bacterial infections, as psychogenic or habit cough, with a
retained foreign body, with gastro-oesophageal reflux, or with persistent bacterial bronchitis. Rarely, it
reflects a serious underlying condition such as a lung malformation, cystic fibrosis (CF), primary
ciliary dyskinesia or immunodeficiency [16]. Finally, exercise-induced respiratory problems are frequent
in children with asthma, but can have other causes such as vocal cord dysfunction, laryngomalacia, or
primary hyperventilation [17].
Many studies have investigated the epidemiology of childhood asthma. Most were conducted in the general
population, such as the International Study on Asthma and Allergies in Childhood (ISAAC) [18, 19], or in
birth cohorts [20–24]. Population-based studies are useful for investigating asthma incidence; however, as
most children in birth cohorts are healthy or have mild disease, they are of limited utility for studying
phenotypes and long-term course. As such, even large cohorts have limited statistical power for studying
long-term outcomes of clinically relevant disease. In addition, population-based studies typically rely on
questionnaires and simple measurements such as spirometry and allergy tests.
Several clinical cohorts of children with asthma have been established [25–28]. However, their inclusion
criteria emphasise asthma alone (e.g. requiring a diagnosis of suspicion of asthma) and do not fully represent
the broad mix of phenotypes seen in healthcare. To our knowledge, no multicentre cohort studies have
focused on children with recurrent cough as the sole symptom and children with exercise-related symptoms.
Although abundant diagnostic and clinical data are routinely collected by the healthcare system these are
rarely used for research. They are of limited value if collected retrospectively from patient records, but can
be very valuable if collected prospectively in a standardised way. The Swiss Paediatric Airway Cohort
(SPAC) was set up in 2017 as a large, longitudinal database representative of children and adolescents
visiting physicians in Switzerland for recurrent wheeze and cough, and exercise-related respiratory
symptoms. The SPAC will constitute a national research platform for studying healthcare provision,
phenotypes and prognosis, and a sampling frame for conducting nested studies. This article explains the
SPAC’s aims and its methods, and outlines how the data can be accessed for future research.
Study objectives
The SPAC is a multipurpose cohort study of children seeking medical care for common lower respiratory
problems (cough, wheeze and dyspnoea). Its objectives are: 1) to describe the spectrum and relative
frequency of respiratory problems in children visiting pulmonary outpatient clinics and paediatric practices
in Switzerland; 2) to distinguish clinical phenotypes of wheeze and cough, and describe associations with
physiological traits and measurements; 3) to investigate long-term trajectories and their determinants, and
to develop and improve clinical prediction tools; 4) to document diagnostic practises, treatment strategies
and preventive measures used in healthcare in Switzerland; 5) to act as a sampling frame for identifying
and recruiting children for specific nested studies.
Methods
Study design
The SPAC is a national multicentre observational study which is integrated into the routine care given
by hospitals and practices. Patients are managed according to local procedures and policies with no
interference from the study team. No examinations are performed specifically for the SPAC and
baseline information is collected prospectively when patients visit the clinic for the first time.
Follow-up data are collected by different means, including: medical data from follow-up appointments,
questionnaires sent yearly to the families (parents or children themselves from the age of 16 years) and
monthly symptom scores assessed via a responsive web application. The study has no specified
endpoint, is hosted at the Institute of Social and Preventive Medicine (ISPM, hereafter called the SPAC
data centre) at the University of Bern, Switzerland and is managed in close collaboration with all
participating SPAC clinics.
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Study population
Inclusion criteria and participating centres
Patients are included in the SPAC if they are referred to a paediatric respiratory outpatient clinic (or visit a
primary care physician repeatedly) for lower respiratory problems such as wheeze, cough, or dyspnoea, or
exercise-related breathing problems. This includes children with concomitant upper respiratory symptoms
such as sinusitis, rhinitis or adenoid hyperplasia. Eligible patients must be below 17 years old, resident in
Switzerland and able to speak sufficient German or French to answer the questionnaire. Exercise-related
breathing problems can be wheeze, cough, chest tightness or dyspnoea triggered by exercise.
Excluded children are those with a prior diagnosis of a severe lung disease, such as CF, primary ciliary
dyskinesia, severe heart disease, oncological disease, neuromuscular disease, or severe disability (diseases
for which there are specific registries) [29]. The SPAC also excludes children who are referred specifically
to perform sleep studies for evaluation of sleep-disordered breathing. Exclusion criteria are deliberately
few in order to allow the recruitment of a study population representative of the entire spectrum of
common lower respiratory problems in childhood, including pre-school viral wheeze, chronic cough and
exercise-related problems.
In the first phase, we aim to recruit children from outpatient clinics at all of the major paediatric hospitals
in Switzerland (Basel, Bern, Zurich, Lucerne, St. Gallen, Aarau, Lausanne and Geneva). At a later stage, we
will open the study to smaller hospitals and paediatric practices.
Study procedures
Patient identification and recruitment
Set in different clinics and practices, SPAC logistics vary slightly between centres because systems for
planning, inviting and organising patient visits differ ( figure 1). Families receive a SPAC information
package containing an invitation letter, study information leaflet, informed consent form and
questionnaire either in the letter that invites them to the clinic, or upon arrival at the hospital. In
both cases, physicians introduce the study to them, answer questions and collect informed consent
forms. Families return the completed questionnaire sent to them ahead of time during their visit to
the clinic. In the case where clinics distribute the questionnaire upon arrival, families send it directly
to the SPAC study centre using a prepaid return envelope. Families who consent but fail to return the
questionnaire are mailed a reminder letter with another questionnaire and a prepaid return envelope
after 4 weeks. If families do not respond to the first reminder letter, they receive a second reminder
2 months after the first reminder.
Clinical assessments and collection of data from hospital records
No tests are performed specifically for the SPAC and examinations such as lung function, allergy, blood
and bronchial challenge tests are performed only if clinically indicated or if requested by the referring
physician (using the respective standard procedures in the clinics involved). The SPAC research team
members visit participating centres at regular intervals. Relevant data are extracted from paper and
electronic hospital records and entered into the SPAC database.
Follow-up data
One year after enrolment in the SPAC, caregivers or patients who are 16 years of age or older will receive a
follow-up questionnaire by email, text message (sms), or post (figure 2). This will be repeated yearly.
Nonresponders will receive a second copy of the follow-up questionnaire after 4–6 weeks and those who
do not respond to the second mailing will be contacted by phone. Provided sufficient funding is available,
we will also collect medical data from follow-up visits. Beginning in 2019, we will ask for short monthly
updates on symptoms, treatments and healthcare utilisation using a simple smart phone app. This will
provide prospective data on respiratory symptoms during the year following the baseline medical visit.
What information is collected
Information from questionnaires
At baseline, families complete a detailed questionnaire that includes sections on frequency, duration,
severity, triggers and history of upper and lower respiratory symptoms, as well as diagnoses, treatments,
health behaviours, environmental factors, family history and contact information (table 1).
The follow-up questionnaires are shorter and focus on symptoms, treatments and important risk factors
during the past 12 months (table 1). Postal addresses for mailing are obtained from hospital records and
updated by contacting community registration offices, a procedure used successfully for other registries
and cohort studies in Switzerland [30]. Questionnaires are currently available in German, but will be
translated into French.
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Information from medical records
Information obtained from medical records includes reasons for referral, anthropometric measures, results
from physical examinations and diagnostic tests (including pulmonary function tests (PFTs), allergy tests
and blood tests), final diagnoses and prescribed treatments (table 1).
Information from the mobile app
From 2019 onwards, parents of participating children and children aged 12 years or older will
complete a short questionnaire on symptoms, exacerbations, emergency visits, hospitalisations and use
of medication through a simple mobile app. This app will be an adapted version of an existing app
called “e-symptoms”, developed jointly by the Allergiezentrum Schweiz (www.aha.ch) and CK-Care
(www.ck-care.ch) foundations.
Step 1: Patient recruitment Step 2: Data collection
Prior to the consultation
Patients receive the SPAC package:
  By post with the invitation
    to the outpatient clinic
  By hand at the SPAC clinic
The SPAC package contains:
  Invitation letter to the study
  Study information and consent form
  Baseline questionnaire
  Prepaid envelope to return the
    documents
In the consultation
Physician informs patients and parents
about SPAC and registers consent. The
signed informed consent form and
study questionnaire may be returned
at the consultation or by post
Patients not participating in the
study
Minimal data (name, sex, date of birth)
is recorded to allow comparison with
included patients and check for sample
representativeness
Step 3: Data entry and storage
Step 4: Data analysis
Baseline
Personal data
Name, address, date of birth,
contact information
Baseline questionnaire
Symptoms, treatment,
medical history, health
behaviours, environment
Medical data (clinic)
Clinical test results,
diagnoses, treatment
Follow-up
Updated personal data
Name, address, date of birth,
contact information
Follow-up questionnaire
Symptoms, treatment, health
behaviours, environment
Mobile app
Symptoms, exacerbations,
healthcare utilisation,
treatment
Central database (REDCap)
No consent
Linking routine data
Swiss national cohort (SNC)
Swiss birth statistics
Hospital episode statistics
Swiss mortality statistics
Identifiable data
Analysed by SPAC data
centre (ISPM)
Pseudo-anonymised data
May be analysed by
collaborators
FIGURE 1 Schematic chart of data collected in the Swiss Paediatric Airway Cohort (SPAC). REDCap: Research Electronic Data Capture (www.
project-redcap.org); ISPM: Institute of Social and Preventive Medicine.
Patient and parents Invitation for visit Baseline visitat clinic Follow-up Follow-up Follow-up
Time
1-6 weeks 12 months 24 months 36 months
Study documents
sent/given to
eligible patients
Study explained
and consent asked
for by the physician
Mobile app
(monthly during
1 year)
Follow-up questionnaire sent every
12 months and data collection from
records if there are repeated visits
Study team
FIGURE 2 Timeline and follow-up procedures of the Swiss Paediatric Airway Cohort.
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Linkage to routine data
For specific analyses, we will use probabilistic record linkage to merge data from the SPAC with routine
datasets collected by the Swiss Federal Statistical Office, as was done for the Swiss Childhood Cancer
Registry (SCCR) [31–33]. This includes information on birth and mortality statistics, national censuses
and hospital episode statistics. These data have been linked to build the Swiss National Cohort (SNC), a
longitudinal research platform including the entire population of Switzerland [34]. This allows perinatal data,
causes of hospitalisations and deaths, socioeconomic indicators and spatially distributed environmental
exposures (such as traffic-related air pollution) to be obtained.
Study database
The SPAC database is web-based, using the Research Electronic Data Capture (REDCap) platform
developed at Vanderbilt University (www.project-redcap.org). REDCap is widely used in academic
research and allows data entry and extraction in various formats. The REDCap environment is completely
secure and only a limited number of research staff from the SPAC research team will have access to the
whole dataset. Furthermore, principle investigators at the participating clinics will have access to data from
TABLE 1 Description of data collected for the Swiss Paediatric Airway Cohort (SPAC)
Source Baseline Follow-up
Questionnaire data
Reason for referral X
Colds and coughing (frequency, duration, history, severity and triggers) X X
Wheeze (frequency, duration, history, severity and triggers) X X
Exercise-related breathing problems (frequency, duration, history, severity and triggers) X X
Ear, nose and throat (frequency, duration, history and severity of specific conditions, e.g. rhinitis, hay fever and otitis) X X
Sleeping problems (frequency, duration, history and severity of specific conditions, e.g. sleep apnoea) X X
Skin (frequency, duration, history, severity and location of specific conditions, e.g. eczema) X X
Diagnosis and treatment (number of visits to the GP or paediatrician, causes for visiting a physician, tests
performed, medication taken (inhaler medication, oral medication, nasal sprays, eye drops and antibiotics), other
chronic illnesses, alternative treatments and vaccinations)
X X
Lifestyle and environment (physical activity, sedentary behaviour, smoking, pets, living on a farm, mould in the
house and humidifier use)
X X
Origin and family (citizenship, siblings, parental education and profession, family history of asthma, hay fever
and eczema)
X
Perinatal factors (pregnancy complications, gestational age, birth weight and length, and breastfeeding) X
Contact information (address, telephone number and email address) X X
Data from medical records
Personal information (date of birth, sex, referring physician and responsible primary care physician) X
Disease (diagnoses, dates and results of diagnostic testing, and prescribed treatments) X
Measurements# (weight, height, PFTs (e.g. spirometry and plethysmography), FeNO, spiroergonometry or other
exercise challenge tests, bronchial challenge tests (e.g. mannitol and methacholine), allergy tests (total IgE, RAST
and SPT), laboratory tests (blood cell count, inflammatory markers and blood gas analysis), imaging (radiography,
CT scan and MRI), microbiology (BAL, sputum and smear), oxygen saturation and PtcO2, bronchoscopy, and special
examinations used for differential diagnosis (e.g. chloride sweat test))
X
Mobile app data
Symptoms (ear, nose, throat, cough, dyspnoea and wheezing) X
Exacerbations (acute worsening of respiratory symptoms) X
Healthcare utilisation (hospitalisations and emergency care visits) X
Treatment (respiratory symptoms medication) X
Routine data and linkage
SNC (environmental exposures (for special analyses) and socioeconomic measures (maternal and paternal
education and profession, number of rooms and persons per household, square meter living space per person
and area-based socioeconomic position index))
X
Swiss birth statistics¶ (gestational age, birth weight and height, and head circumference) X
Hospital episode statistics¶ (type of hospital, length of stay, type of discharge, referral pathways, diagnosis and
treatments (ICD-10, procedure and DRGs))
X
Swiss mortality statistics¶ (date and cause of death (ICD-10), age, sex, profession, place of residence and citizenship) X
GP: general practitioner; PFT: pulmonary function test; FeNO: exhaled nitric oxide fraction; RAST: radio allergo sorbent test; SPT: skin prick
test; CT computed tomography; MRI: magnetic resonance imaging; BAL: bronchoalveolar lavage; PtcO2: transcutaneous oxygen tension; SNC:
Swiss National Cohort; ICD-10: international classification of diseases-10th revision; DRG: diagnosis related group. #: only if measurements
are taken for clinical reasons; ¶: birth, hospital episode and mortality statistics will be obtained from the Swiss Federal Statistical Office.
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only their own clinic. Data entered through the mobile app will be automatically forwarded via a secure
connection to a central, secure database accessible only by the study team.
Ethics and data protection
Ethical approval for the study was obtained from the Bern Cantonal Ethics Committee (Kantonale
Ethikkommission Bern 2016-02176). Written informed consent to participate in the study is obtained
from patients’ parents or directly from patients of 14 years of age or older. Patients can withdraw their
consent and their data from the SPAC study at any time by contacting the SPAC clinic or the SPAC data
centre. Data generation, transmission and storage, as well as analysis of health-related personal data within
the SPAC study, follow the current Swiss legal requirements for data protection. Employees are trained in
data protection and must sign an agreement for dealing with particularly sensitive data.
Study power and sample size
We plan to recruit at least 3000 patients for the SPAC. This number is based on project feasibility and the
annual number of patients seen in the paediatric respiratory outpatient clinics in Switzerland. For children
with asthma (an estimated 60–70% of the cohort) this number will allow us to perform analyses such as
latent class analyses that involve models with numerous parameters. For developing prognostic models, 10
events are required for each predictor variable entered into the model. A large sample size is also needed to
study rarer outcomes such as chronic cough, vocal cord dysfunction and emergency hospital admissions.
After reaching 3000 patients, recruitment will continue on a reduced scale, focusing on specific diagnostic
subgroups or patients of higher severity.
How data can be accessed
Participating centres have continual access to their own datasets and can export them directly in various
formats for local analyses. The study of SPAC data from several centres is regulated by the SPAC
committee, which consists of the SPAC clinics and members of the SPAC data centre. Researchers who
wish to use data should submit a concept sheet describing the planned analysis to the SPAC committee
for approval (see supplementary material). If the SPAC Committee agrees, a publication agreement (see
supplementary material) is signed and the SPAC data centre prepares a partial dataset for the proposed
analysis. The SPAC data centre will work closely with and support the lead researchers of each study.
Researchers who wish to develop a nested study with inclusion of additional data also need to submit a
proposal to the SPAC committee and request permission. Additional data collected by nested studies
must be contributed to the SPAC database after the study. Nested studies might also need separate
ethics permission.
Current status and initial results
The first clinics (Lucerne, Bern, Zurich and Basel) began recruiting patients in 2017. During the first
months, procedures were revised to fit the requirements of each centre. Currently, 60–80 new patients
enter the SPAC every month and enrolment is accelerating (figure 3). St. Gallen and Aarau plan to join in
2018, Lausanne and Geneva in 2019.
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FIGURE 3 Number of participants in the Swiss Paediatric Airway Cohort, from study start in July 2017 to
March 2018.
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Until March 2018, 347 out of 851 eligible patients (41%) consented and returned the baseline
questionnaire (table 2). In addition, there were 16 eligible patients who consented but have yet to return
the baseline questionnaire. Participation rates varied significantly between hospitals and were 88%, 64%,
33% and 29%, respectively, in the four centres (Lucerne, Bern, Zurich and Basel), with lower response
rates in larger hospitals. Of the patients who participated, 29% were aged less than 5 years, 33% were aged
5–9 years and 38% were aged 10–15 years. Sixty-two percent were males. During the past 12 months, 64%
had wheezed, 50% had night cough apart from colds, 60% had exercise-induced symptoms and 13% had
habitual snoring (on most nights). In older children, wheeze and night cough were less common than in
younger ones, while exercise-induced symptoms were more common. About 19% of mothers and 28% of
fathers smoked, 4% of children lived on a farm and 34% kept pets at home. During the past 12 months,
75% had used a short-acting bronchodilator and 56% had used an inhaled corticosteroid (ICS).
Discussion
The nationwide and multicentre SPAC is a clinical cohort of children visiting physicians for recurrent
wheeze, cough, dyspnoea and exercise-induced respiratory problems. Patients are currently recruited from
outpatient clinics of major paediatric hospitals, but smaller hospitals and primary care practices will be
invited to join so that the SPAC will include the full spectrum of patients with common respiratory
problems in Switzerland. The key features of the SPAC are shown in text box 1.
Only a few comparable clinical cohorts have been set up in other countries. One is the All Age Asthma
Cohort (ALLIANCE), a national cohort of paediatric and adult patients with asthma in Germany, led by
the German Centre for Lung Research (DZL) and registered at https://clinicaltrials.gov with identifier
NCT02496468. ALLIANCE aims to identify biomarkers and predictors of different wheeze phenotypes
and their longitudinal course. It differs in several aspects from the SPAC in that it recruits patients with a
doctor’s diagnosis of asthma and healthy controls, and performs an extensive set of measurements in all
TABLE 2 Characteristics of participants in the Swiss Paediatric Airway Cohort (SPAC) by March 2018
Characteristics Total participants
(n=347)
Participants by age
<5 years (n=99) 5–9 years (n=116) ⩾10 years (n=132)
Study centre
Bern 87 (25) 27 (27) 26 (22) 34 (26)
Zurich 129 (38) 31 (31) 41 (35) 57 (43)
Lucerne 102 (29) 35 (35) 41 (35) 26 (20)
Basel 29 (8) 6 (6) 8 (7) 15 (11)
Demographics
Age years 8±4 3±1 7±1 13±2
Male sex 214 (62) 67 (68) 68 (59) 79 (60)
Symptoms#,¶
Wheeze 217 (63) 77 (78) 76 (66) 64 (48)
Cough at night apart from colds 167 (48) 48 (48) 61 (53) 58 (44)
Rhinitis apart from colds 188 (54) 43 (43) 67 (58) 78 (59)
Exercise-induced respiratory symptoms 200 (58) 36 (36) 63 (54) 101 (77)
Habitual snoring (most nights) apart from colds 46 (13) 10 (10) 15 (13) 21 (16)
Environmental exposures¶
Maternal smoking 64 (18) 19 (19) 18 (16) 27 (20)
Paternal smoking 93 (27) 29 (29) 26 (22) 38 (29)
Living on a farm 15 (4) 6 (6) 3 (3) 6 (5)
Pets at home 118 (34) 22 (22) 38 (33) 58 (44)
Mould in the house 34 (10) 15 (15) 11 (9) 8 (6)
Physical activity
Not very active 31 (9) 3 (3) 7 (6) 21 (16)
Moderately active 223 (64) 58 (59) 74 (64) 91 (69)
Very active 93 (27) 38 (38) 35 (30) 20 (15)
Treatment history¶
Used inhaled SABA 259 (75) 82 (83) 95 (82) 82 (83)
Used ICS 184 (59) 55 (63) 59 (57) 70 (58)
Data is displayed as n (%) or mean±SD. SABA: short-acting β-agonists; ICS: inhaled corticosteroids; ISAAC: International Study of Asthma and
Allergies in Childhood. #: questions on symptoms were based on questions used in the ISAAC study, either alone or in combination (e.g.
pulmicort, axotide, seretide and symbicort); ¶: data as recorded over the past 12 months.
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children, including single and multiple breath wash-out tests and biomaterial collection (blood, swabs,
stool and induced sputum samples) for “omics” studies. Two cohorts from the Netherlands studied
preschool children seen in general practice for cough or suspected asthma. One was set up between
1995–1997 [27] and one between 2004–2006 (the ARCADE cohort) [28]. Both followed the children until
the age of 6 years and, as in ALLIANCE, these cohorts focused on asthma. They were regional, not
nationwide, recruiting participants only from primary care. The Childhood Asthma Management
Programme (CAMP) started as a randomised controlled trial (RCT) of over 1000 children aged 5–12 years
with asthma who were randomised to receive treatment with budesonide, nedocromil, or a placebo in eight
clinical centres in the US and Canada [25, 26]. Follow-up was extended after the randomisation to study
long-term outcomes. As for the other studies mentioned, inclusion criteria were narrow requiring mild to
moderate asthma. A strength of this study is that all children received a full set of diagnostic tests and
repeated clinical follow-up assessments, including multiple lung function tests.
The SPAC contrasts with all these studies because it is a real-life picture of a representative sample of all
children visiting physicians for recurrent wheeze, cough, dyspnoea and exercise problems. Thus it does not
only include children with typical doctor-diagnosed asthma, but the entire range of children with less
typical features, whose diagnosis is often a challenge for paediatricians and pulmonologists. This setting
(consecutive referrals) allows us to assess the value of screening tests, which is not possible in a
case-control setting. The SPAC includes not only asthma, but also has a focus on chronic cough and
exercise-induced dyspnoea of different aetiologies, both of which are under-researched entities. Being
multicentre and observational, the SPAC includes a large proportion of the children referred for evaluation
of respiratory disease in Switzerland and allows us to monitor healthcare practise (diagnostics and
management) by both referring primary care physicians and hospitals.
This design also leads to weaknesses. First, although inclusion criteria are comprehensive, the study
population is not totally representative. Recent immigrants, who do not speak French or German, are not
eligible for the study. In addition, the response rate varied between hospitals from 29% to 88%, suggesting
that in some clinics participants are not fully representative of all patients. Furthermore, not all hospitals
currently participate and patients seen only in primary care are not currently part of the SPAC. However,
despite these limitations, the SPAC represents the mix of patients seen in Switzerland better than a
RCT would do, or a prospective study with a fixed set of measurements. Secondly, results from some
measurements, such as bronchial challenge tests, will only be available for some patients, and the order
and procedures for clinical examinations vary between hospitals. For example, hospitals use different
protocols to perform exercise challenge tests. We intend to harmonise these procedures in the future
where possible, but the SPAC will remain a real-life observational study. This variation might improve
over time because the SPAC provides an opportunity for collaborating centres to harmonise their
examinations and the ongoing harmonisation process of the Swiss Personalised Health Network will
lead eventually to a more uniform set of data being collected in Swiss hospitals. Thirdly, the lack of
sophisticated lung function tests, immunological examinations and biosamples limits the ability of the SPAC
to perform deep endophenotyping. Some of these aspects will, however, be covered in nested studies.
In summary, the SPAC will provide a unique resource for studying the pathophysiology, clinical
phenotypes and long-term course of common respiratory problems in children, as well as for assessing
and comparing aspects of healthcare across Switzerland. This will make it an important research platform
for clinical and translational studies on common respiratory problems in children.
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• Research platform for nested studies.
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